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Abstract The current recommended therapy for Kawasaki
disease (KD) is the combination of intravenous immuno-
globulin (IVIG) and aspirin. However, the role of cortico-
steroid therapy in KD remains controversial. Using meta-
analysis, this study aimed to investigate the efficacy of
corticosteroid therapy in KD by comparing it with standard
IVIG and aspirin therapy. We included all related random-
ized and quasi-randomized controlled trials by searching
Medline, the Cochrane Central Register of Controlled
Trials, EMBASE, Pub Med, Chinese BioMedical Literature
Database, China National Knowledge Infrastructure, and
the Japanese database (Japan Science and Technology) as
well as hand searches of selected references. Data collection
and meta-analysis were performed to evaluate the effect of
corticosteroids. Our search yielded 11 studies; 7 of which
evaluated the effect of corticosteroid for primary therapy in
KD, and 4 investigated the effect of corticosteroid therapy
in IVIG-resistant patients. Meta-analysis of these studies
revealed a significant reduction in the rates of initial
treatment failure among patients who received corticoste-
roid therapy in combination with IVIG compared to IVIG
alone (odds ratio (OR)=0.50; 95% CI, 0.32~0.79; p=
0.003). Furthermore, the use of corticosteroids reduced the
duration of fever and the time required for C-reactive
protein to return to normal. Our data did not show any
significant increase in the incidence of coronary artery
lesions or coronary aneurysms (OR=0.67; 95% CI,
0.35~1.28; p=0.23) in the corticosteroid group. Conclusion.
Corticosteroid combined with IVIG in primary treatment or
as treatment of IVIG-resistant patients improved clinical
course without increasing coronary artery lesions in children
with acute KD.
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Introduction
Kawasaki disease (KD) is the leading cause of acquired
heart disease among children in developed countries [18]. It
is an acute, self-limited, systemic vasculitis of unknown
etiology that typically presents in early childhood. The
disease is characterized by fever, bilateral nonexudative
conjunctivitis, erythema of the lips and oral mucosa,
changes in the extremities, rash, and cervical lymphade-
nopathy [12]. Although the etiology of KD is unknown,
clinical and epidemiological data strongly suggest an
infectious origin. Identification is typically based on the
presence of specific signs and symptoms with selected
laboratory findings, such as C-reactive protein.
As the most important complication, coronary artery
lesions may lead to myocardial infarction, ischemic heart
disease, and sudden death. Since the 1980s, when intrave-
nous immunoglobulin (IVIG) combined with high-dose
aspirin was demonstrated to reduce the prevalence of
coronary abnormalities [13, 16, 26], this regimen has
gradually become the standard therapy for the treatment
of KD. Nevertheless, approximately 15% of patients fail to
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DOI 10.1007/s00431-011-1585-4respond to initial IVIG treatment and are more likely to
develop coronary aneurysms indicating the need for
alternative treatment modalities [2, 18, 24, 26, 29].
Systemic immune activation in acute phase plays an
important role in the pathogenesis of KD. Corticosteroids
suppress the immune response and have strong anti-
inflammatory effects. Considering the pathogenesis of Kawa-
saki disease, it is reasonable to believe that corticosteroids
would suit the disease management. However, an early study
in 1979 suggested that corticosteroids were associated with
increased risk of coronary aneurysms. Since then, cortico-
steroids were restricted in the treatment of KD [11]. However,
the number of patients treated with steroids was small and
flaws existed in their methodology, thus the results of this
study cannot be considered conclusive. Subsequent studies
suggested that corticosteroid treatment in Kawasaki disease
compared with IVIG shortened the duration of fever without
increasing the incidence of coronary artery lesions or serious
adverse events [13, 15, 16, 27, 28]. The efficacy and safety
of corticosteroid therapy for Kawasaki disease continue to
remain controversial [1, 5, 14, 17, 19, 23, 24]. Therefore, we
tried to evaluate the clinical effects of corticosteroid
treatment on KD by performing a meta-analysis of recent
clinical controlled studies in order to seek a better treatment
regimen for Kawasaki disease.
Methods
Search methods
Search terms included: Kawasaki disease or mucocutaneous
lymph node syndrome, hormones, glucocorticoids, predni-
sone,methylprednisolone,hydrocortisone,ordexamethasone.
Each search consisted of a combination of a minimum of one
term from each group.
Study sources included: the Cochrane Library, Medline,
EMBASE, Pub Med, Chinese BioMedical Literature
Database, China National Knowledge Infrastructure, and
Japan Science and Technology. These databases, as well as
related references, were used to identify published studies
which investigated the overall effect of corticosteroids in
the treatment of Kawasaki disease. All subjects are pediatric
patients. Preliminary studies were first identified by
screening the titles and abstracts of candidate articles. After
reviewing the full text, studies meeting the inclusion criteria
were finally included. Conflicts in the above process were
resolved by discussion among the authors.
Criteria for inclusion
Studies were included when they met the following criteria:
randomized controlled, clinical trials, case-controlled or
comparison studies evaluating the efficacy of corticoste-
roids alone or in combination with IVIG therapy in the
treatment of Kawasaki disease. All subjects in the selected
studies were diagnosed with Kawasaki disease (Japan
Kawasaki Disease Research Committee [9]; American
Heart Association's diagnostic criteria [3]). Studies not
meeting the above criteria were excluded.
Evaluation of outcome data
The following criteria were used to measure outcomes: the
incidence of coronary artery lesions, duration of fever and
changes in serum C-reactive protein levels after treatment, the
rate of unresponsive patients to initial treatment (persistent
fever lasting for more than 36 h, temperature >38°C, or
recrudescent fever associated with KD symptoms after an
afebrile period, 2–7d a y s )[ 5], and the number/presence of
adverse events.
Statistical analysis
Data analysis were performed with meta-analysis software
(RevMan 5.0) provided by the Cochrane Collaboration net.
The proportion of patients who developed coronary
aneurysms and the non-responsive rate in each study were
converted to odds ratio (OR) and the duration of fever and
C-reactive protein (CRP) levels after treatment were
expressed with mean±standard deviation (mean±SD). Ho-
mogenous results utilized the fixed effects model (Peto
method) for statistical analysis. The random effects model
(DerSimonian–Laird method) was employed for heteroge-
neous results and the data were presented using a forest map.
Results
Description of included studies
Search of public databases and selected references using the
previously described criteria yielded 510 articles. Initial
evaluation of titles and abstracts identified 22 related
articles. The remaining works were excluded due to
duplication, non-clinical trials, or failure to meet inclusion
criteria. Further evaluation of the identified 22 articles
resulted in an additional elimination of 11 articles. These
articles evaluated corticosteroid therapy as part of the
primary treatment (n=7) and as additional therapy (n=4)
for IVIG-resistant patients [6–8, 10, 14, 17, 19–21, 22, 25].
Six of the studies were randomized controlled studies with
one prospective, multicenter, double-blind randomized
controlled trial [17]. One study divided patients into two
subgroups for analysis. The subjects of nine studies were
Japanese and the remaining were from North America
572 Eur J Pediatr (2012) 171:571–578[17, 25]. Characteristics of all included studies are
presented in Tables 1 and 2. No significant differences in
age, sex, and illness were found between the two therapy
groups at enrollment. Seven studies involved a follow-up
period ranging from 1 to 50 months [7, 8, 10, 17, 21, 22, 25].
Statistical analysis suggested no significant differences
between age, sex, and severity of illness between the two
study groups.
Evaluation of outcome
Seven studies and a total of 933 patients were included in
the primary treatment regimen, of which 563 patients
received corticosteroid plus conventional therapy (aspirin
+ IVIG) or corticosteroid with aspirin. The control group
received conventional therapy or aspirin alone. Four studies
and a total of 122 patients were included in additional
treatment regimens. In this group, 74 patients received
corticosteroid therapy after treatment with conventional
therapy failed and the control groups received additional
IVIG. Aspirin was administered to all patients. Meta-
analyses of the incidence of coronary artery lesions are
shown in Figs. 1 and 2.
Coronary artery lesions
The outcomes of administering corticosteroid as primary
treatment (n=8) were combined with fixed effects model.
The results showed no significant increase in the incidence
of coronary artery lesions (CAL) (OR=0.53; 95% CI,
0.27~1.04; p=0.07) in the corticosteroid group compared
with that in the control group. In the eight studies evaluated
(seven plus one subgroup study, see Shinohara et al. [22]),
four showed a reduction in CAL in the corticosteroid group
compared to the control with only one study showing
higher incidence of CAL in the corticosteroid group; one
study was not analyzed for no CAL events [21]. Subjects of
one study were high-risk KD patients [20] and one was a
retrospective study [22].
The use of corticosteroid therapy as additional treatment
(n=4) resulted in no significant increase in the incidence of
CALs (OR=0.87; 95% CI, 0.32~2.36; p=0.78) compared
with the control group. Within the studies evaluated, two
showed no significant reduction of CAL and one showed
fewer CALs in the corticosteroid group. The study
conducted by Hashino et al. suggested higher incidence of
CAL, with three patients experiencing transient coronary
artery dilatation which returned to baseline diameter values
21 days after re-treatment [7]. Meta-analysis of the
incidence of coronary artery aneurysms (CAA) at 1 month
after treatment is shown in Fig. 3.
There were a total of four studies including 424 patients
that evaluated the incidence of coronary artery aneurysms
1 month after the initiation of treatment. This included two
randomized controlled studies. Three of the four studies
evaluated corticosteroid therapy for primary treatment, and
one group assessed the effects of corticosteroids on IVIG-
resistant patients. There were no significant differences in
the incidence of coronary artery aneurysms (OR=0.67;
95% CI, 0.35~1.28; p=0.23) in the treatment group
compared with the control group.
Duration of fever after treatment
Due to the existence of significant heterogeneity among
selected studies, only four studies with similar treatment
protocols were combined to evaluate the effect of cortico-
steroid therapy on the duration of fever after treatment. The
Table 1 Summary of patients receiving corticosteroids in initial treatment
Study Patient characteristics Aspirin IVIG Corticosteroid
Total
patients
Therapy
group
Sex
(male %)
Age
(year)
Therapy
day
mg/kg
per day
g/kg
per dose
No. of
doses
Drug
preparation
Dosage
(mg/kg per day)
Duration of
therapy (days)
Newburger
et al. [17]
199 101 62 2.9 10 80–100 2 1 IVMP 30 1
Inoue et al. [8] 178 90 57.3 4.5 9 30 1 2 Pred 2 3
Okada et al. [21] 32 14 56.3 2.8 9 30 1 2 Pred 2 3
Sundel et al. [25]3 9 1 8 6 9 1 0 2 0 –25 2 1 IVMP 30 1
Okada et al. [20] 94 62 77.4 2.8 6 30 2 1 IVMP 30 1
Jibiki et al. [10] 92 46 48.9 2.3 7 30 0.4 or 0.5 4–5 Dex 0.3 3
Shinohara
et al. 1 [22]
212 170 –– 9 30 0 0 Pred 2 Defervescence
Shinohara
et al. 2 [22]
87 62 –– 9 30 0.2 or 0.4 5 Pred 2 Defervescence
IVMP intravenous methylprednisone, Pred prednisolone
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criteria of temperature normalization among the studies, the
heterogeneity still existed among the four included studies
(p=0.03, I
2=68%); a random effects model was used for
the analysis (Fig. 4).
Febrile days tended to be shorter in the corticosteroid
group than that in the IVIG group in one study and were
significantly shorter in two other studies. The outcome of
the four studies indicates there is a significant reduction in the
duration of fever after corticosteroid therapy (MD=−1.30,
p=0.0005).
Inflammatory markers
CRP is typically elevated in acute KD, usually returning to
normal by 6 to 10 weeks after onset of the illness.
Therefore we compared the changes of CRP level in the
acute phase after treatment. There were nine studies that
assessed changes in CRP level after treatment [7, 8, 10, 14,
17, 19–21, 25]. The differences in CRP between groups at
baseline were not significant, but for obvious heterogeneity
and incomplete data in six articles, only three studies were
finally evaluated by meta-analysis [10, 14, 19]. As a result,
outcomes of two studies indicated that CRP decreased more
rapidly after corticosteroid therapy and one showed no
significant difference. Combined analysis showed a signif-
icant statistical difference in CRP level after two therapy
regimens (MD=−0.16, p=0.02) (data not shown).
The rate of non-response to initial treatment
Five studies with 601 patients were analyzed, the number of
non-responsive patients were those with persistent fever
lasting for more than 36 h (temperature >38°C) or
recrudescent fever associated with KD symptoms after an
afebrile period (2–7 days). The meta-analysis is shown in
Fig. 5.
Four of the included studies were randomized controlled
trials, while one was a quasi-randomized controlled study.
All four randomized controlled studies showed a lower
non-response rate to corticosteroid therapy than to IVIG
alone. The remaining study showed no significant differences
Table 2 Summary of patients receiving corticosteroids as additional treatment
Study Patient characteristics Aspirin IVIG Corticosteroid
Total
patients
Therapy
group
Sex
(male %)
Age
(year)
Therapy
day
mg/kg
per day
g/kg per
dose
No. of
doses
Drug
preparation
Dosage (mg/kg
per day)
Duration of
therapy (days)
Ogata S
et al. [19]
27 14 – 2.5 9 30 2 1 IVMP 30 3
Miura
et al. [14]
15 7 66.7 2.6 9 – 2 1 IVMP 30 3
Hashino
et al. [7]
17 9 – 6.3 9 30 1 1 IVMP 20 3
Furukawa
et al. [6]
63 44 54 2.4 8 30 1–2 3 IVMP 30 3
Study or Subgroup
Inoue et al[8]
Jibiki et al[10]
Newburger et al[17]
Okada et al[21]
Okada et al[20]
Shinohara et al1[22]
Shinohara et al2[22]
Sundel et al[25]
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.41; Chi² = 13.46, df = 6 (P = 0.04); I² = 55%
Test for overall effect: Z = 1.83 (P = 0.07)
Events
2
2
30
0
15
21
1
4
75
Total
90
46
99
14
62
170
62
16
559
Events
10
2
28
0
15
8
6
3
72
Total
88
46
93
18
32
42
25
21
365
Weight
11.6%
8.3%
23.5%
19.2%
19.4%
7.3%
10.6%
100.0%
M-H, Random, 95% CI
0.18 [0.04, 0.83]
1.00 [0.13, 7.42]
1.01 [0.54, 1.87]
Not estimable
0.36 [0.15, 0.89]
0.60 [0.24, 1.47]
0.05 [0.01, 0.46]
2.00 [0.38, 10.58]
0.53 [0.27, 1.04]
Odds Ratio Odds Ratio IVIG IVIG + Corticosteroids
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental   Favours control
Fig. 1 The incidence of coronary artery lesions after primary treatment
574 Eur J Pediatr (2012) 171:571–578between the two therapy protocols in which patients received
dexamethasone 0.3 mg/kg per day for 3 consecutive days.
Combining outcomes of the five studies demonstrated a
significant reduction in the number of patients needing
re-treatment between the two therapy regimens (OR=0.50;
95% CI, 0.32~0.79; p=0.003).
Additional clinical outcomes
There were four included studies that compared hospitali-
zation days and cost in the corticosteroid group with that in
the IVIG group. Six studies were excluded in the present
meta-analysis of CRP, but their respective results regarding
CRP were consistent with this study. Three studies
confirmed that corticosteroid therapy reduced the duration
of hospital stay and costs. However, Newburger et al. [17]
reported dissimilar results. They concluded that two
matched groups had similar total number of days in the
hospital (including readmissions) and days of fever after the
onset of illness or after randomization. Two included
articles also investigated the effects of corticosteroid (added
to primary therapy or as part of additional treatment) on
serum cytokine levels in the acute phase of KD. The
findings demonstrated that TNF-α and MCP-1 were
significantly inhibited after steroid therapy [14], which
suggests steroid therapy may prevent the development of
coronary aneurysm and improve clinical signs and
symptoms.
Adverse events related to steroid therapy included sinus
bradycardia, hypothermia, hypertension, and hypokalemia;
all of which were transient and later spontaneously
recovered [6, 8, 17, 19, 20]. Newburger et al. reported four
serious events, including shock, profound sensorineural
hearing loss, and respiratory failure with negative blood
cultures 3 days after initial hospital discharge in the
methylprednisolone group [17]. They also reported a
possible nonocclusive thrombus in the right coronary artery
by echocardiography in the control group. One study
reported that one patient in the IVIG group developed
shock shortly after IVIG administration [8] and Okada et al.
found some patients developed transient AST elevation
[20]. Sundel et al. reported that one patient in the steroid
group developed idiopathic thrombocytopenic purpura and
later died due to bilateral pulmonary and left cerebellar
hemorrhages [25]. This was not believed to be related to
KD or steroid treatment.
Study or Subgroup
Furukawa et al[6]
Hashino et al[7]
Miura et al[14]
Ogata S et al[19]
Total (95% CI)
Total events
Heterogeneity: Chi² = 2.38, df = 3 (P = 0.50); I² = 0%
Test for overall effect: Z = 0.28 (P = 0.78)
Events
5
7
2
0
14
Total
44
9
7
13
73
Events
2
5
2
3
12
Total
19
8
8
14
49
Weight
30.0%
14.3%
16.2%
39.5%
100.0%
M-H, Fixed, 95% CI
1.09 [0.19, 6.18]
2.10 [0.25, 17.59]
1.20 [0.12, 11.87]
0.12 [0.01, 2.61]
0.87 [0.32, 2.36]
Corticosteroids IVIG Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental   Favours control
Fig. 2 The incidence of coronary artery lesions following failure of primary treatment and after secondary treatment. Secondary treatment
consisted of either corticosteroids or a second round of IVIG
Study or Subgroup
Hashino et al[7]
Inoue et al[8]
Newburger et al[17]
Sundel et al[25]
Total (95% CI)
Total events
Heterogeneity: Chi² = 1.59, df = 3 (P = 0.66); I² = 0% 
Test for overall effect: Z = 1.21 (P = 0.23)
Events
4
0
15
1
20
Total
9
90
95
18
212
Events
5
3
18
1
27
Total
8
88
95
21
212
Weight
13.1%
15.6%
67.4%
3.9%
100.0%
M-H, Fixed, 95% CI
0.48 [0.07, 3.35]
0.13 [0.01, 2.65]
0.80 [0.38, 1.70]
1.18 [0.07, 20.26]
0.67 [0.35, 1.28]
Corticosteroids/+IVIG IVIG Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental   Favours control
Fig. 3 The incidence of coronary artery aneurysms at 1 month after treatment
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Forty years have passed since the first description of
Kawasaki disease, yet the etiology remains unknown.
Therefore the optimal treatment awaits identification of
the specific agent or agents and pathogenic mechanisms of
the disease. Presently, IVIG and aspirin are the recom-
mended standard therapy for treatment with the occasional
use of steroids. However, the role and potential adverse
effects of the use of steroids in KD remain controversial.
There have been recent reports of successful management
of IVIG-resistant patients and patients with serious compli-
cations of KD receiving additional steroid therapy resulting
in no serious adverse effects [4, 8, 14]. Additional studies
have reported the use of steroids as part of the primary
treatment with no increase in the incidence of coronary
artery lesions, shortened hospitalization days and duration
of fever, reduced CRP, erythrocyte sedimentation rate, and
other inflammatory indictors [8, 10, 17, 21, 25]. We believe
this data supports the need to reevaluate the role of
corticosteroid in Kawasaki disease.
This meta-analysis is a systematic review integrating
results of individual studies in a quantitative method. With
the increase in use of evidence-based medicine in recent
years, meta-analysis has become an important tool in
clinical medicine. Although it can be difficult to avoid
publication bias, this type of examination improves the test
power by combining several small clinical trials into a large
clinical trial, especially when the results of the included
studies contain inconsistencies. This analysis systematically
evaluated the efficacy and safety of corticosteroid therapy
in KD.
Comparison of the incidence of coronary artery lesions
Whether in primary treatment or as additional treatment,
our study does not indicate a significant increase in the
incidence of coronary artery lesions following steroid
therapy. Yet, one study showed a lower incidence of CAL
in the steroid group compared to the control; we considered
this was the result of missing data. Two patients missed
echocardiograms at the 2-week visit that were included at
the 1-month follow-up echocardiogram. The data indicated
no significant difference in the incidence of coronary artery
aneurysms between the two groups at this time point;
therefore, indicating steroid therapy does not increase the
incidence of coronary artery aneurysms, irrespective of
whether it was used as primary treatment or as additional
Study or Subgroup
Inoue et al[8]
Jibiki et al[10]
Okada et al[21]
Sundel et al[25]
Total (95% CI)
Heterogeneity: Tau² = 0.36; Chi² = 9.29, df = 3 (P = 0.03); I² = 68%
Test for overall effect: Z = 3.46 (P = 0.0005)
Mean
0.6
2.2
0.3
1
SD
0.5
2.7
0.5
1.3
Total
90
46
14
18
168
Mean
1.5
2.8
2.9
2.4
SD
1
3
2.4
1.9
Total
88
46
18
21
173
Weight
37.7%
19.7%
20.2%
22.5%
100.0%
IV, Random, 95% CI
-0.90 [-1.13, -0.67]
-0.60 [-1.77, 0.57]
-2.60 [-3.74, -1.46]
-1.40 [-2.41, -0.39]
-1.30 [-2.03, -0.56]
Experimental Control Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours experimental   Favours control
Fig. 4 Comparison of the duration of fever after treatment in patients that received corticosteroid plus IVIG or IVIG alone
Study or Subgroup
Inoue et al[8]
Jibiki et al[10]
Newburger et al[17]
Okada et al[20]
Sundel et al[25]
Total (95% CI)
Total events
Heterogeneity: Chi² = 3.84, df = 4 (P = 0.43); I² = 0%  
Test for overall effect: Z = 2.97 (P = 0.003)
Events
5
6
12
21
2
46
Total
90
46
101
62
18
317
Events
16
6
15
18
5
60
Total
88
46
97
32
21
284
Weight
28.4%
9.7%
25.1%
29.2%
7.6%
100.0%
M-H, Fixed, 95% CI
0.26 [0.09, 0.76]
1.00 [0.30, 3.37]
0.74 [0.33, 1.67]
0.40 [0.17, 0.95]
0.40 [0.07, 2.37]
0.50 [0.32, 0.79]
Experimental Control Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental  Favours control
Fig. 5 The rate of unresponsive patients to initial treatment
576 Eur J Pediatr (2012) 171:571–578treatment for IVIG resistant. On the contrary, there have
been reports indicating that high-risk KD patients or IVIG-
resistant patients treated with corticosteroid displayed a
reduction in the incidence of coronary aneurysms [8, 20].
Results of patients non-responsive to standard therapy
Analysis of four randomized controlled studies showed a
marked decrease in the number of febrile patients after
corticosteroid therapy. These data indicated that corticoste-
roid therapy does not increase the incidence of coronary
artery lesions in high-risk children or patients refractory to
IVIG therapy. Although the use of steroids did not
significantly reduce the risk of coronary artery lesions in
children with KD, our data demonstrated it does shorten the
duration of fever and reduce the number of patients
requiring re-treatment with IVIG or other pharmacologic
protocols. Several studies suggested that corticosteroids
improved the laboratory inflammatory findings and made
C-reactive protein and cytokines levels decrease rapidly in
the acute phase of KD [8, 14, 20, 21, 25]. In contrast, a
randomized study by Newburger et al. demonstrated that
pulse intravenous methylprednisolone (30 mg/kg over 2 to
3 h) administered before IVIG in primary treatment did not
improve coronary artery outcome or reduce the total days of
hospitalization or fever [17]. Although important, these
differences may be attributed to differences in protocols of
corticosteroid therapy. The data supports the beneficial use
of corticosteroid in the treatment of Kawasaki disease for
primary treatment or as additional treatment after initial
therapy failure. According to the results of this study and
previous reports, IVIG therapy is not completely effective
and alternative primary or additional therapies should be
considered. The present power of the prediction of non-
response rate to initial therapy with IVIG alone is limited
and the late sequelae of systemic vasculitis remain
unknown in KD patients, even in those without acute
coronary artery injury [20]. Undoubtedly, coronary lesions
are the greatest risk of fatality in predominant determinants
of its outcome; moreover, a full picture of the outcome of
Kawasaki disease remains unclear. So the application of
corticosteroid to treating Kawasaki disease deserves further
discussion.
Limitations
The majority of reports using corticosteroid therapy in
Kawasaki disease are retrospective studies often with an
increase in bias due to a lack of experimental controls.
Randomized controlled studies are one of the most rigorous
experimental designs utilized in evidence-based medicine;
only six of the included studies in this report were
randomized controlled studies. However, the dosage and
administration of corticosteroid, immunoglobulin, aspirin,
and other additional drugs varied among the included
studies (see Tables 1 and 2). Furthermore, the studies
included were of small sample size and could contribute to
bias. Therefore, to further verify the efficacy and safety of
steroid therapy in the treatment of Kawasaki disease, larger,
prospective, multicenter, randomized controlled studies
should be conducted.
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